Microbix Forms Special Workgroup to Double Flu Vaccine Output

September 13, 2007
BioPharm International Editors

Microbix Biosystems Inc. (Toronto, Canada, www.microbix.com), is establishing a special workgroup for applied technology transfer (SWATT) that will help manufacturers significantly boost the amount of flu vaccine produced throughout the world.

Microbix Biosystems Inc. (Toronto, Canada, www.microbix.com), is establishing a special workgroup for applied technology transfer (SWATT) that will help manufacturers significantly boost the amount of flu vaccine produced throughout the world. The SWATT team will be sent to facilities adopting Microbix’s proprietary virus yield enhancement technology, called Virusmax. The team is expected to be operational this fall. It will spend several weeks in each location helping customers implement the technology and training local personnel. At present, only about 350 million doses of flu vaccine are produced annually in the world, with only three countries producing enough vaccine domestically to immunize their populations.